Rani Therapeutics Holdings (RANI) Debt to Equity (2020 - 2025)
Rani Therapeutics Holdings (RANI) has 6 years of Debt to Equity data on record, last reported at -$1.13 in Q3 2025.
- For Q3 2025, Debt to Equity fell 123.07% year-over-year to -$1.13; the TTM value through Sep 2025 reached -$1.13, down 123.07%, while the annual FY2024 figure was $7.05, 510.19% up from the prior year.
- Debt to Equity reached -$1.13 in Q3 2025 per RANI's latest filing, up from -$1.88 in the prior quarter.
- Across five years, Debt to Equity topped out at $7.05 in Q4 2024 and bottomed at -$3.91 in Q1 2025.
- Average Debt to Equity over 5 years is $1.0, with a median of $0.43 recorded in 2022.
- Peak YoY movement for Debt to Equity: skyrocketed 199690.27% in 2023, then plummeted 293.11% in 2025.
- A 5-year view of Debt to Equity shows it stood at $0.0 in 2021, then soared by 37902.63% to $0.39 in 2022, then skyrocketed by 193.18% to $1.15 in 2023, then surged by 510.19% to $7.05 in 2024, then crashed by 116.05% to -$1.13 in 2025.
- Per Business Quant database, its latest 3 readings for Debt to Equity were -$1.13 in Q3 2025, -$1.88 in Q2 2025, and -$3.91 in Q1 2025.